Charles River Laboratories International, Inc. (CRL)

227,81 -11,62 (-4,85%) Börsenschluss: 04:00PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 20.400

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. James C. Foster J.D.	CEO, President & Chairman	2,66M	N/A	1951
Ms. Flavia H. Pease	Corporate Executive VP & CFO	1,66M	N/A	1973
Ms. Birgit Girshick	Corporate Executive VP & COO	1,28M	464,88k	1970
Mr. Joseph W. LaPlume	Corporate Executive Vice President of Corporate Development & Strategy	928,36k	262,98k	1974
Mr. William D. Barbo	Corporate Executive Vice President of Community Relations	1M	399,92k	1961
Mr. Michael Gunnar Knell	Corporate Senior VP & Chief Accounting Officer	N/A	N/A	1977
Prof. Julie Frearson Ph.D.	Corporate Senior VP & Chief Scientific Officer	N/A	N/A	N/A
Mr. Mark Mintz	Corporate Senior VP & Chief Information Officer	N/A	N/A	N/A
Todd Spencer	Corporate Vice President of Investor Relations	N/A	N/A	N/A
Mr. Matthew L. Daniel	Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate Governance

Charles River Laboratories International, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.